Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 16Lymphoid 15Myeloid 10Gastrointestinal 5Classical hematology 5Plasma cell 4Dermatologic 4Sarcoma 3Other solid neoplasm 2Genitourinary 2Thoracic 1Other neoplasm 1NET 1Gynecologic 1Endocrine 1CNS 1

Conditions

Recurrence 1Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 35Bevacizumab 31Carboplatin 29pembrolizumab 25Specimen Handling 20Magnetic Resonance Spectroscopy 18olaparib 16Cisplatin 15liposomal doxorubicin 13Taxes 12Immunoglobulin G 11Gemcitabine 11Disulfides 11Topotecan 9Nivolumab 9Cyclophosphamide 9Biopsy 8fludarabine 7Doxorubicin 7mirvetuximab soravtansine 6niraparib 5Radiation 5Oxaliplatin 5Fulvestrant 5Fluorouracil 5trastuzumab deruxtecan 4durvalumab 4cediranib 4Platinum 4Megestrol Acetate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
fludarabine phosphate × Gynecologic × 30 days × Clear all
NCT06305299 2026-05-19

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
27 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡